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Abstract 
Data from clinical trials involving human participants are essential in establishing an evidence base 
about the safety and effectiveness of our treatments. This second article describes the steps involved in 
designing and setting up a clinical trial, from writing a protocol to gaining the necessary approvals. 
Acquiring some knowledge about how to set up a clinical trial will allow the conscientious clinician to 
use the most relevant information to provide the highest possible standards of clinical care for their 
patients. 
Clinical relevance statement 
Even if a clinician is not, has never been, nor is ever planning to be involved in research, they should 
understand and be able to interpret the data from clinical trials. 
Objectives statement 
The reader should understand the importance of the research question(s) and have some knowledge 
about what should be included in a protocol for a clinical trial. 
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Introduction  
This article will describe the steps involved in designing and setting up a clinical trial, from writing a 
protocol to gaining the necessary approvals. 
 
How to write a protocol  
Study setting and location 
The number (single or multi-centre), location (country), types of settings and care providers involved 
(e.g. primary, secondary, tertiary or community) must be determined. These will influence the 
generalisability and relevance of the trial to other settings and therefore the ability to guide clinical 
practice and policy.1 
Eligibility criteria  
The main research question will aid researchers to determine the type of participants required (Figure 
1).  Clear inclusion and exclusion criteria are required to recruit suitable participants and simplify 
implementation of the trial. The eligibility criteria will allow others to interpret in which patients the 
results of the trial will apply. Baseline participant characteristics should be collected during the clinical 
trial for the same purpose.1 
Sample size calculation 
All clinical trials involve selecting a group of individuals (i.e. the sample), from a population, usually 
with a particular condition. The sample group is investigated and the results are used to infer that a 
similar outcome would occur in all individuals with that condition, because it is not practical to include 
all individuals with that condition in a study. 
Before starting the trial, it is necessary to try to estimate how many participants should be included in 
the study. The reasons for this are both ethical and practical. It would be unethical to start a study unless 
there were sufficient participants to have a reasonable chance of answering the research question 
posed. Also, individuals are putting themselves at risk (however small) when volunteering to 
participate in a study with an unknown outcome, and ethically you would not want to put more 
individuals at risk than is absolutely necessary. Practically, only a certain amount of funding and time 
will be available to run the trial and therefore it would not be possible to include an endless number of 
participants. 
There are a number of excellent articles about how to undertake a sample size calculation.2 It is common 
to recruit a few participants more than the sample size calculation initially suggests, to account for an 
inevitable number being lost to follow-up, either through withdrawal or dropout. 
Recruitment 
It is important to describe how participants will be identified and recruited.  The recruitment process 
(e.g. referral, self-selection through advertisement, financial incentives) must be described in the 
protocol. Recruitment can be time consuming and a realistic amount of time should be allowed for this. 
The dates of recruitment should be defined, as this will affect the generalisability of the trial (e.g. 
accepted medical and surgical practices continually change and this could affect the routine/control 
treatment given to patients).1 
Interventions  
All interventions should be thoroughly described, including any control interventions, to allow other 
clinicians to reproduce the methods.1 Interventions should only be administered once the participant 
has been enrolled in the trial, according to the chosen method of assignment. 
Blinding 
The protocol should describe who will be blinded (i.e. unaware of participant assignment) to the 
intervention group(s), including the trial participants, treating clinicians, and outcome assessors. 
Outcomes 
Prior to undertaking the trial, the primary and secondary outcomes must be predefined.1 It is important 
to have one primary outcome (or at most two). This is the outcome that is judged to be of single most 
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importance to all stakeholders and which could be used to answer the main question/focus of the 
study.1 The time point(s) when the primary outcome data is to be assessed should also be decided. This 
is used to estimate how many participants should be recruited to the trial.  
Multiplicity of primary outcomes, as well as statistical testing, should be avoided, as this reduces clarity 
and increases the risk of spurious findings (e.g. finding a statistically significant difference by chance).1 
There can be several secondary outcomes (e.g. including harms), but the same needs to be borne in 
mind. 
The Core Outcome Measures in Effectiveness Trials Initiative (COMET) is an organisation which 
supports the development  Ǯ  ǯ ȋȌǤ3 These are agreed, standardised sets of 
outcomes, which represent the minimum that should always be measured and reported in clinical trials 
of a specific condition. COS allow the results of different studies to be compared and combined, as 
appropriate. 
Once the primary and secondary outcomes have been defined, it is necessary to determine valid 
outcome measurement tools.  It is usually best to use an existing tool that has a proven track record and 
has been tested for validity and reproducibility. This will enhance quality and allow comparisons with 
other studies.1 Other important considerations include, who will make the assessments, if there will be 
any masking of allocation during measurement (blinding) and if there will be any means of determining 
the consistency of measurements by the same rater (intra-rater repeatability) and/or between raters 
(inter-rater reproducibility). 
Follow-up and end-points 
The time-points of assessment (frequency) and the endpoint of assessment (duration of follow-up) 
should be explicit and clinically appropriate to answering the primary research question. 
Informed consent  
An assessment of capacity must be performed on all potential participants within a trial and written 
informed consent obtained.(1,4,5)  Information should usually be given verbally, through discussion and 
in another form (e.g. written, audio-visual etc.) which should be outlined in the protocol. This should 
include the trial aims, methods, potential benefits/risks, post-study arrangements and any other 
relevant aspects (e.g. sources of funding, possible conflicts of interest, researcher affiliations etc.).6 
Participants must have the opportunity to ask questions, told that they do not have to take part and can 
withdraw consent at any time, without it affecting their treatment.  
Flow of patients through the trial 
The Consolidated Standards of Reporting Trials (CONSORT) group recommend explicitly describing the 
flow of participants through the study when reporting randomised trials, including the reasons for 
exclusions and loss to follow-up. A CONSORT flow diagram (Figure 2) must be planned in the protocol 
and completed within the trial.7 This will allow others to judge how much the estimated effect of the 
intervention might be over or under-exaggerated in comparison with ideal circumstances.1 
Interim analysis and stopping guidelines  
This is usually at pre-determined time-points and involves analysing the interim results, with or 
without maintaining the blinding present.1 If an intervention is showing larger than expected benefits 
or harms, or no important difference, the data monitoring (and ethics) committee can recommend that 
the trial continues, is modified or stopped earlier than planned.5 
Statistical methods  
Statistical methods can be used to compare the groups in the trial for both the primary and secondary 
outcomes.1 Additional analyses, such as subgroup analyses and adjusted analyses can be undertaken, 
but care should be exercised to avoid increasing the risk of finding spurious results. 
An intention-to-treat analysis is often recommended for RCTs, as any missing participant data in the 
analyses (i.e. due to exclusion, loss to follow-up and/or deviations from the protocol) will compromise 
the randomisation and may lead to bias.1 An intention-to-treat analysis involves analysing all 
participants that were enrolled and randomised, in the exact groups to which they were randomised to. 
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This can be quite difficult if there is missing data.1 Solutions might include imputing the final outcomes 
or less favourably, carrying the last known observation forward.1  
Post-trial provisions  
Before the trial starts, access to treatments found beneficial, after the trial has finished, should be 
considered and this information disclosed during the consenting process.5 
Obtaining funding and support grants  
The cost of the trial should be considered at the protocol stage. Money can be obtained from industry 
(e.g. new medicinal product, device or technology), a research funding body (e.g. NIHR or Medical 
Research Council) or from a charity (e.g. the British Orthodontic Society Foundation).  
Three types of research costs are defined by the Department of Health (DH):8  
x Research costs Ȃ these are related to activities carried out to answer the research question (e.g. data 
collection and analysis, and are usually met by the funders of the trial); 
x Treatment costs Ȃ these are related to patient care, and are usually met through the normal NHS 
commissioning process; 
x NHS service support costs Ȃ these are related to additional activities, which are part of the research 
process, rather than the treatment, (e.g. consenting patients for the study, and are usually 
administered through the local Clinical Research Networks (CRNs)). 
For a commercial research trial (e.g. pharmaceutical company) the NHS is required to recover all costs, 
over and above the standard NHS treatment, from industry. 
Sponsorship  
A sponsor is required for any research involving patients, their tissues or NHS resources.(6, 9)  The 
sponsor can be defined as an individual, company (e.g. pharmaceutical company), institution (e.g. 
university hosting the research), or organisation (e.g. NHS organisation), which assumes overall 
responsibility for starting and managing the trial, and is not necessarily the main funder. These 
responsibilities may be shared by joint- or co-sponsors.  A risk assessment is usually undertaken using 
the study protocol and a decision made about whether to grant sponsorship or not. If successful, a letter 
of sponsorship is issued.  Sponsorship is required prior to any other approvals.10 
Peer review 
Finally, the protocol should be scientifically peer reviewed by a number of independent clinicians and 
preferably patients as well. It may be necessary to make changes to the protocol during the trial, in 
response to changing circumstances, but such changes should be transparent and acknowledged during 
reporting, to allow a reasonable interpretation of the results.1 
Approvals required to commence a trial within the UK 
After the protocol, funding and sponsorship have been agreed, the necessary legal permissions and 
approvals must be sought.10 
Ethical and regulatory considerations 
Clinical trials require ethical11 and research governance6 approval. Other approvals that may be 
required, including the Medicine and Healthcare Products Regulatory Agency (MHRA).12 The process 
for approval has been simplified, with an online system called the Integrated Research Application 
System (IRAS).13 This is a single, stream-lined system to apply for permissions for health and social care 
research in the UK.  With this system, the information for the trial can be entered onto one form and 
IRAS will automatically update the information onto all of the relevant approval forms. 
IRAS captures the relevant approvals from the following review bodies: 
x Administration of Radioactive Substances Advisory Committee (ARSAC) 
x Confidentiality Advisory Group (CAG) 
x Gene Therapy Advisory Committee (GTAC) 
x Health Research Authority (HRA) for projects seeking HRA Approval 
x Medicines and Healthcare Products Regulatory Agency (MHRA) 
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x NHS / HSC Research and development offices (R&D) 
x NHS / HSC Research Ethics Committees (REC) 
x Social Care Research Ethics Committee (REC) 
Once completed, the forms are transferred electronically to the appropriate organisations, along with 
any supporting documentation (e.g. participant information sheets and consent forms).  Depending on 
what is involved in the study, compliance with other regulatory bodies may be required including 
ionising radiation (IRMER), Medicines for Human Use (Clinical Trials) Regulations (2004) etc. 
Data protection, patient confidentiality and Caldicott guardians  
Privacy and confidentiality for research participants and their personal information are essential.5 
Caldicott guardians are individuals within an organisation, who should be notified of all research and 
related activities, to ensure that any patient identifiable information (PII) used complies with the 
Caldicott principles14 and Data Protection Act.15   
Indemnity insurance  
All trials should be covered by some form of indemnity insurance, either through the hospital trust or 
university. 
Trial registration 
All clinical trials must be registered on a publically accessible database.(1, 5) Trial registration and 
publication helps prevent duplication, non-publication and selective reporting of outcomes.  There are 
several trial registration sites to choose from, and once registered, a unique trial registration number 
is given. 
Common trial reference numbers 
IRAS number: Generated by IRAS and will be the primary reference number for the trial used by REC, 
HRA and if applicable MHRA.  
EudraCT number: It is now compulsory that all clinical trials of investigational medicinal products 
(CTIMPs) are registered on the EudraCT database.16 
Clinical trials register number: Acceptable registers include EU Clinical Trials Register,17 International 
Standard Randomised Controlled Trials Number (ISRCTN) Register18 and ClinicalTrials.gov.19 
Sponsors number: Generated by the sponsor 
Funders number: Generated by the funder 
Roles and responsibilities of trial team and committees  
Trial team 
Chief Investigator: The named Chief Investigator (CI) is responsible for the conduct of the research (e.g. 
design, management, reporting) in the UK and, if at more than one site, the co-ordination of the Principal 
Investigators. 
Principal Investigator:  The Principal Investigator (PI) is responsible for their own research site. 
In a single-site study, the CI and PI will usually be the same person. Other members of the trial team 
might include a trial co-ordinator/manager, research nurse, data manager, programmer, site monitor, 
statistician, health economist, data entry/clerical support etc. 
Trial committees 
Trial Management Committee: Meets regularly to ensure all practical details of the trial are progressing 
and everyone understands the processes. 
Trial steering committee: Meets regularly to ensure that the trial is running well and sends reports to 
the sponsor. The majority of its members must be independent of the trial (including the chair), and it 
is desirable to include experienced trial researchers and patient representatives.20 
Data monitoring (and ethics) committee: Scrutinizes the study progression and its members must be 
independent of the trial.20 
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Training requirements for researchers and Good Clinical Practice (GCP) 
The international ethical, scientific and practical standard for conducting clinical research is called 
Good Clinical Practice (GCP).(21, 22) All individuals conducting a trial should be suitably educated, trained 
and experienced to perform their tasks.21 GCP compliance reassures the public that the rights, safety 
and wellbeing of research participants are protected and the research data is reliable.23  Depending ǯǡ
ning.23 
Typical trial time line  
A typical clinical trial time line is: 
x Set-up (9 months) 
x Recruitment (2 years) 
x Follow-up (1-3 years) 
x Analysis (6 months) 
Dissemination 
Once participants have been recruited, data collected and analysed, a report must be prepared and 
disseminated, so the results can be used in clinical practice. If this is not done, then the contributions of 
the researchers and participants will have been wasted. There are many ways of publicising the results, 
usually through a conference presentation and publication in a suitable academic journal (preferably 
open access). There are a number of statements that outline what should be included in the report of a 
clinical trial to ensure quality and transparency of reporting. The appropriate statement to use depends 
upon the design of the study (Table 1) and most can be found on the Equator Network.24 
Summary 
This second article has described the steps involved in designing and setting up a clinical trial from 
writing a protocol to gaining the necessary approvals. Clinicians should be aware of how research is 
undertaken. Without a reasonable knowledge about how data, related to the safety and effectiveness of 
treatments is obtained, it would be challenging to undertake appropriate evidence-based clinical 
practice. 
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Figure captions  
Figure 1: Deciding on the study sample for the trial 
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Figure 2: CONSORT flow diagram (Available from http://www.consort-statement.org) 
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Tables  
Table 1: Reporting statements for different trial designs (Available from: 
http://www.equator-network.org) 
 
 
